Clinical Context
A typical patient is an adult or adolescent with severe eosinophilic asthma or eosinophilic granulomatosis with polyangiitis receiving subcutaneous biologic therapy. The patient presents to an outpatient infusion clinic, specialty pharmacy clinic, or physician office for administration of J2182 (mepolizumab, 1 mg). The clinical workflow includes verification of patient identity and insurance, review of recent clinical notes and indication, confirmation of recent blood eosinophil count and prior authorization status, preparation of the prefilled syringe or vial, administration via subcutaneous injection, observation for immediate adverse reactions (typically 15–30 minutes), and documentation of lot number, dose, route, site, and any reactions.
Typical site of service: outpatient infusion clinic, specialty clinic, injection suite, or physician office.
Common clinical scenario: a patient with uncontrolled severe eosinophilic asthma on inhaled controller therapy with elevated blood eosinophils who qualifies for mepolizumab by guideline criteria and payer coverage, returns every 4 weeks for subcutaneous injection. The visit includes review of control, interval adverse events, and recording of medication administration details.